Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients
Glioblastoma multiforme (GBM) is the most common and aggressive primary human brain tumour in adults with an average survival of 11 months. The 2‐year survival is less than 10%, and only a small proportion of patients are alive at 3 years. Despite improved treatment strategies and aggressive therapy...
Gespeichert in:
| Veröffentlicht in: | Neuropathology and applied neurobiology 2006-08, Vol.32 (4), p.410-418 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 418 |
|---|---|
| container_issue | 4 |
| container_start_page | 410 |
| container_title | Neuropathology and applied neurobiology |
| container_volume | 32 |
| creator | Oblinger, J. L. Pearl, D. K. Boardman, C. L. Saqr, H. Prior, T. W. Scheithauer, B. W. Jenkins, R. B. Burger, P. C. Yates, A. J. |
| description | Glioblastoma multiforme (GBM) is the most common and aggressive primary human brain tumour in adults with an average survival of 11 months. The 2‐year survival is less than 10%, and only a small proportion of patients are alive at 3 years. Despite improved treatment strategies and aggressive therapy, the prognosis of GBM has changed little in past decades. Thus, any test that can reliably and rapidly diagnose the tumour and predict patient survival could be a valuable tool. Herein we report the use of quantitative real‐time polymerase chain reaction (PCR) to quantify five glycosyltransferase transcripts in gliomas. Our results indicate that measuring GM1 synthase (β‐1,3 galactosyltransferase) mRNA may provide a useful method for segregating GBMs from other types of gliomas. In these studies, 97% of gliomas (36/37 tumours) below a threshold value had a diagnosis of GBM compared with 49% (52/106 tumours) above the threshold. More importantly, the increased expression of GD3 synthase mRNA in combination with decreased GalNAcT message correlated with increased survival in 79 GBM patients (proportional hazards model controlling for age, P = 0.02). These data were further corroborated by a data analysis from one of our previous studies on gangliosides of 80 GBMs, in which increased amounts of GM3 and GD3 (which accumulate in the absence of GalNAcT) correlated with a longer survival (P |
| doi_str_mv | 10.1111/j.1365-2990.2006.00742.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68680467</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19336587</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5312-f485bfd2f457a6284dbb7a68a6e500dcfe17bfbe9b535d13d2784b3fa2deb16d3</originalsourceid><addsrcrecordid>eNqNkUuP0zAUhS0EYsrAX0DZwC7B7zgSm2qAAakqEg-NxMayY3vk4sTFTqD99zi0zCzBG1_rfsf2PQeACsEGlfVq1yDCWY27DjYYQt5A2FLcHB6A1V3jIVhBAlmNBOUX4EnOOwgha3n3GFwgLjjvBF8B-car2zHmyfeVGk21T_Hv8acKs62iq27DsY_5GKakxuxsUtlWw6ftuvJj6fmog8pTHFQ1zGHyLqbBVns1eTtO-Sl45FTI9tl5vwRf3739cvW-3ny8_nC13tQ9IwjXjgqmncGOslZxLKjRuhRCccsgNL2zqNVO204zwgwiBreCauIUNlYjbsgleHm6twzwY7Z5koPPvQ1BjTbOWZaBBaS8_SeIOlIcFAsoTmCfYs7JOrlPflDpKBGUSwpyJxez5WK2XFKQf1KQhyJ9fn5j1oM198Kz7QV4cQZU7lVwxdje53uu7SjCjBbu9Yn75YM9_vcH5Ha9LUWR1ye5z5M93MlV-i6LEy2TN9tr-e1zRyC52ciW_AacirP_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19336587</pqid></control><display><type>article</type><title>Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Oblinger, J. L. ; Pearl, D. K. ; Boardman, C. L. ; Saqr, H. ; Prior, T. W. ; Scheithauer, B. W. ; Jenkins, R. B. ; Burger, P. C. ; Yates, A. J.</creator><creatorcontrib>Oblinger, J. L. ; Pearl, D. K. ; Boardman, C. L. ; Saqr, H. ; Prior, T. W. ; Scheithauer, B. W. ; Jenkins, R. B. ; Burger, P. C. ; Yates, A. J.</creatorcontrib><description>Glioblastoma multiforme (GBM) is the most common and aggressive primary human brain tumour in adults with an average survival of 11 months. The 2‐year survival is less than 10%, and only a small proportion of patients are alive at 3 years. Despite improved treatment strategies and aggressive therapy, the prognosis of GBM has changed little in past decades. Thus, any test that can reliably and rapidly diagnose the tumour and predict patient survival could be a valuable tool. Herein we report the use of quantitative real‐time polymerase chain reaction (PCR) to quantify five glycosyltransferase transcripts in gliomas. Our results indicate that measuring GM1 synthase (β‐1,3 galactosyltransferase) mRNA may provide a useful method for segregating GBMs from other types of gliomas. In these studies, 97% of gliomas (36/37 tumours) below a threshold value had a diagnosis of GBM compared with 49% (52/106 tumours) above the threshold. More importantly, the increased expression of GD3 synthase mRNA in combination with decreased GalNAcT message correlated with increased survival in 79 GBM patients (proportional hazards model controlling for age, P = 0.02). These data were further corroborated by a data analysis from one of our previous studies on gangliosides of 80 GBMs, in which increased amounts of GM3 and GD3 (which accumulate in the absence of GalNAcT) correlated with a longer survival (P < 0.01). Thus, measuring GalNAcT and GD3 transcripts may provide a rapid method to assess prognosis in GBM patients. In summary, the data indicate that measuring glycosyltransferase mRNA levels by real‐time PCR may be clinically useful for determining both diagnosis and prognosis in GBM patients.</description><identifier>ISSN: 0305-1846</identifier><identifier>EISSN: 1365-2990</identifier><identifier>DOI: 10.1111/j.1365-2990.2006.00742.x</identifier><identifier>PMID: 16866986</identifier><identifier>CODEN: NANEDL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Brain Neoplasms - diagnosis ; Brain Neoplasms - mortality ; Chemotherapy ; diagnosis ; Diagnosis, Differential ; Endocrinopathies ; gangliosides ; Glioblastoma - diagnosis ; Glioblastoma - mortality ; glioblastoma multiforme ; Glioma - diagnosis ; glycosyltransferases ; Glycosyltransferases - biosynthesis ; Glycosyltransferases - genetics ; Humans ; Hypothalamus. Hypophysis. Epiphysis (diseases) ; Medical sciences ; Neurology ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Pharmacology. Drug treatments ; Prognosis ; real-time reverse transcription polymerase chain reaction ; Reverse Transcriptase Polymerase Chain Reaction - instrumentation ; RNA, Messenger - analysis ; Sensitivity and Specificity ; Survival Analysis ; Survival Rate</subject><ispartof>Neuropathology and applied neurobiology, 2006-08, Vol.32 (4), p.410-418</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5312-f485bfd2f457a6284dbb7a68a6e500dcfe17bfbe9b535d13d2784b3fa2deb16d3</citedby><cites>FETCH-LOGICAL-c5312-f485bfd2f457a6284dbb7a68a6e500dcfe17bfbe9b535d13d2784b3fa2deb16d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2990.2006.00742.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2990.2006.00742.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17941254$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16866986$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oblinger, J. L.</creatorcontrib><creatorcontrib>Pearl, D. K.</creatorcontrib><creatorcontrib>Boardman, C. L.</creatorcontrib><creatorcontrib>Saqr, H.</creatorcontrib><creatorcontrib>Prior, T. W.</creatorcontrib><creatorcontrib>Scheithauer, B. W.</creatorcontrib><creatorcontrib>Jenkins, R. B.</creatorcontrib><creatorcontrib>Burger, P. C.</creatorcontrib><creatorcontrib>Yates, A. J.</creatorcontrib><title>Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients</title><title>Neuropathology and applied neurobiology</title><addtitle>Neuropathol Appl Neurobiol</addtitle><description>Glioblastoma multiforme (GBM) is the most common and aggressive primary human brain tumour in adults with an average survival of 11 months. The 2‐year survival is less than 10%, and only a small proportion of patients are alive at 3 years. Despite improved treatment strategies and aggressive therapy, the prognosis of GBM has changed little in past decades. Thus, any test that can reliably and rapidly diagnose the tumour and predict patient survival could be a valuable tool. Herein we report the use of quantitative real‐time polymerase chain reaction (PCR) to quantify five glycosyltransferase transcripts in gliomas. Our results indicate that measuring GM1 synthase (β‐1,3 galactosyltransferase) mRNA may provide a useful method for segregating GBMs from other types of gliomas. In these studies, 97% of gliomas (36/37 tumours) below a threshold value had a diagnosis of GBM compared with 49% (52/106 tumours) above the threshold. More importantly, the increased expression of GD3 synthase mRNA in combination with decreased GalNAcT message correlated with increased survival in 79 GBM patients (proportional hazards model controlling for age, P = 0.02). These data were further corroborated by a data analysis from one of our previous studies on gangliosides of 80 GBMs, in which increased amounts of GM3 and GD3 (which accumulate in the absence of GalNAcT) correlated with a longer survival (P < 0.01). Thus, measuring GalNAcT and GD3 transcripts may provide a rapid method to assess prognosis in GBM patients. In summary, the data indicate that measuring glycosyltransferase mRNA levels by real‐time PCR may be clinically useful for determining both diagnosis and prognosis in GBM patients.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Brain Neoplasms - diagnosis</subject><subject>Brain Neoplasms - mortality</subject><subject>Chemotherapy</subject><subject>diagnosis</subject><subject>Diagnosis, Differential</subject><subject>Endocrinopathies</subject><subject>gangliosides</subject><subject>Glioblastoma - diagnosis</subject><subject>Glioblastoma - mortality</subject><subject>glioblastoma multiforme</subject><subject>Glioma - diagnosis</subject><subject>glycosyltransferases</subject><subject>Glycosyltransferases - biosynthesis</subject><subject>Glycosyltransferases - genetics</subject><subject>Humans</subject><subject>Hypothalamus. Hypophysis. Epiphysis (diseases)</subject><subject>Medical sciences</subject><subject>Neurology</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>real-time reverse transcription polymerase chain reaction</subject><subject>Reverse Transcriptase Polymerase Chain Reaction - instrumentation</subject><subject>RNA, Messenger - analysis</subject><subject>Sensitivity and Specificity</subject><subject>Survival Analysis</subject><subject>Survival Rate</subject><issn>0305-1846</issn><issn>1365-2990</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUuP0zAUhS0EYsrAX0DZwC7B7zgSm2qAAakqEg-NxMayY3vk4sTFTqD99zi0zCzBG1_rfsf2PQeACsEGlfVq1yDCWY27DjYYQt5A2FLcHB6A1V3jIVhBAlmNBOUX4EnOOwgha3n3GFwgLjjvBF8B-car2zHmyfeVGk21T_Hv8acKs62iq27DsY_5GKakxuxsUtlWw6ftuvJj6fmog8pTHFQ1zGHyLqbBVns1eTtO-Sl45FTI9tl5vwRf3739cvW-3ny8_nC13tQ9IwjXjgqmncGOslZxLKjRuhRCccsgNL2zqNVO204zwgwiBreCauIUNlYjbsgleHm6twzwY7Z5koPPvQ1BjTbOWZaBBaS8_SeIOlIcFAsoTmCfYs7JOrlPflDpKBGUSwpyJxez5WK2XFKQf1KQhyJ9fn5j1oM198Kz7QV4cQZU7lVwxdje53uu7SjCjBbu9Yn75YM9_vcH5Ha9LUWR1ye5z5M93MlV-i6LEy2TN9tr-e1zRyC52ciW_AacirP_</recordid><startdate>200608</startdate><enddate>200608</enddate><creator>Oblinger, J. L.</creator><creator>Pearl, D. K.</creator><creator>Boardman, C. L.</creator><creator>Saqr, H.</creator><creator>Prior, T. W.</creator><creator>Scheithauer, B. W.</creator><creator>Jenkins, R. B.</creator><creator>Burger, P. C.</creator><creator>Yates, A. J.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell Science</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7TM</scope><scope>7X8</scope></search><sort><creationdate>200608</creationdate><title>Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients</title><author>Oblinger, J. L. ; Pearl, D. K. ; Boardman, C. L. ; Saqr, H. ; Prior, T. W. ; Scheithauer, B. W. ; Jenkins, R. B. ; Burger, P. C. ; Yates, A. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5312-f485bfd2f457a6284dbb7a68a6e500dcfe17bfbe9b535d13d2784b3fa2deb16d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Brain Neoplasms - diagnosis</topic><topic>Brain Neoplasms - mortality</topic><topic>Chemotherapy</topic><topic>diagnosis</topic><topic>Diagnosis, Differential</topic><topic>Endocrinopathies</topic><topic>gangliosides</topic><topic>Glioblastoma - diagnosis</topic><topic>Glioblastoma - mortality</topic><topic>glioblastoma multiforme</topic><topic>Glioma - diagnosis</topic><topic>glycosyltransferases</topic><topic>Glycosyltransferases - biosynthesis</topic><topic>Glycosyltransferases - genetics</topic><topic>Humans</topic><topic>Hypothalamus. Hypophysis. Epiphysis (diseases)</topic><topic>Medical sciences</topic><topic>Neurology</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>real-time reverse transcription polymerase chain reaction</topic><topic>Reverse Transcriptase Polymerase Chain Reaction - instrumentation</topic><topic>RNA, Messenger - analysis</topic><topic>Sensitivity and Specificity</topic><topic>Survival Analysis</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oblinger, J. L.</creatorcontrib><creatorcontrib>Pearl, D. K.</creatorcontrib><creatorcontrib>Boardman, C. L.</creatorcontrib><creatorcontrib>Saqr, H.</creatorcontrib><creatorcontrib>Prior, T. W.</creatorcontrib><creatorcontrib>Scheithauer, B. W.</creatorcontrib><creatorcontrib>Jenkins, R. B.</creatorcontrib><creatorcontrib>Burger, P. C.</creatorcontrib><creatorcontrib>Yates, A. J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Neuropathology and applied neurobiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oblinger, J. L.</au><au>Pearl, D. K.</au><au>Boardman, C. L.</au><au>Saqr, H.</au><au>Prior, T. W.</au><au>Scheithauer, B. W.</au><au>Jenkins, R. B.</au><au>Burger, P. C.</au><au>Yates, A. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients</atitle><jtitle>Neuropathology and applied neurobiology</jtitle><addtitle>Neuropathol Appl Neurobiol</addtitle><date>2006-08</date><risdate>2006</risdate><volume>32</volume><issue>4</issue><spage>410</spage><epage>418</epage><pages>410-418</pages><issn>0305-1846</issn><eissn>1365-2990</eissn><coden>NANEDL</coden><abstract>Glioblastoma multiforme (GBM) is the most common and aggressive primary human brain tumour in adults with an average survival of 11 months. The 2‐year survival is less than 10%, and only a small proportion of patients are alive at 3 years. Despite improved treatment strategies and aggressive therapy, the prognosis of GBM has changed little in past decades. Thus, any test that can reliably and rapidly diagnose the tumour and predict patient survival could be a valuable tool. Herein we report the use of quantitative real‐time polymerase chain reaction (PCR) to quantify five glycosyltransferase transcripts in gliomas. Our results indicate that measuring GM1 synthase (β‐1,3 galactosyltransferase) mRNA may provide a useful method for segregating GBMs from other types of gliomas. In these studies, 97% of gliomas (36/37 tumours) below a threshold value had a diagnosis of GBM compared with 49% (52/106 tumours) above the threshold. More importantly, the increased expression of GD3 synthase mRNA in combination with decreased GalNAcT message correlated with increased survival in 79 GBM patients (proportional hazards model controlling for age, P = 0.02). These data were further corroborated by a data analysis from one of our previous studies on gangliosides of 80 GBMs, in which increased amounts of GM3 and GD3 (which accumulate in the absence of GalNAcT) correlated with a longer survival (P < 0.01). Thus, measuring GalNAcT and GD3 transcripts may provide a rapid method to assess prognosis in GBM patients. In summary, the data indicate that measuring glycosyltransferase mRNA levels by real‐time PCR may be clinically useful for determining both diagnosis and prognosis in GBM patients.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>16866986</pmid><doi>10.1111/j.1365-2990.2006.00742.x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-1846 |
| ispartof | Neuropathology and applied neurobiology, 2006-08, Vol.32 (4), p.410-418 |
| issn | 0305-1846 1365-2990 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68680467 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Antineoplastic agents Biological and medical sciences Biomarkers, Tumor - analysis Brain Neoplasms - diagnosis Brain Neoplasms - mortality Chemotherapy diagnosis Diagnosis, Differential Endocrinopathies gangliosides Glioblastoma - diagnosis Glioblastoma - mortality glioblastoma multiforme Glioma - diagnosis glycosyltransferases Glycosyltransferases - biosynthesis Glycosyltransferases - genetics Humans Hypothalamus. Hypophysis. Epiphysis (diseases) Medical sciences Neurology Non tumoral diseases. Target tissue resistance. Benign neoplasms Pharmacology. Drug treatments Prognosis real-time reverse transcription polymerase chain reaction Reverse Transcriptase Polymerase Chain Reaction - instrumentation RNA, Messenger - analysis Sensitivity and Specificity Survival Analysis Survival Rate |
| title | Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A23%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20and%20prognostic%20value%20of%20glycosyltransferase%20mRNA%20in%20glioblastoma%20multiforme%20patients&rft.jtitle=Neuropathology%20and%20applied%20neurobiology&rft.au=Oblinger,%20J.%20L.&rft.date=2006-08&rft.volume=32&rft.issue=4&rft.spage=410&rft.epage=418&rft.pages=410-418&rft.issn=0305-1846&rft.eissn=1365-2990&rft.coden=NANEDL&rft_id=info:doi/10.1111/j.1365-2990.2006.00742.x&rft_dat=%3Cproquest_cross%3E19336587%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19336587&rft_id=info:pmid/16866986&rfr_iscdi=true |